Concord Drugs Ltd — Board Meeting, 23-05-2025: Board Meeting

Concord Drugs Limited has announced a board meeting to approve the financial results for the quarter and half-year. The audited standalone and consolidated results show net sales of Rs. 3,693.21 lakh and Rs. 4,524.46 lakh respectively, with profits before tax of Rs. 64.13 lakh (standalone) and Rs. 69.14 lakh (consolidated). Profit after tax stood at Rs. 29.57 lakh standalone and Rs. 33.62 lakh consolidated. The company reported stable operating performance despite a dip in revenues compared to the previous year. Auditor Pundarikashyam and Associates issued an unmodified opinion, highlighting long outstanding trade receivables of Rs. 4.14 Cr for over two years, without provision for bad debts, and noted balances are subject to confirmations and reconciliation.